RT-GLP3
20mg · $100 · Current batch
Triple agonist peptide used in metabolic and endocrine research settings investigating receptor pathway activity.
Studied as a triple GIP/GLP-1/glucagon receptor agonist in metabolic research models exploring energy expenditure, glucose regulation, and receptor pathway crosstalk.
Purity≥ 98%
FormLyophilized powder
Size Available20mg (bulk available on request)
StorageStore at -20°C. Reconstituted solution should be refrigerated and used within recommended timeframe.
Certificate of AnalysisProvided with every batch — request COA · how to read it
This product is sold strictly for in vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic, is not intended for human or veterinary use, and has not been evaluated by the FDA. Orders are fulfilled only to verified researchers and institutions. See our research use disclaimer.
Research & References
Published literature relevant to this peptide's studied mechanisms and research use. Provided for reference — not a claim of safety or efficacy for any use outside laboratory research.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial PubMed
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials PubMed
- A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight ClinicalTrials.gov — NCT07232719
